Overview

The Gene Technology Act 2000, enacted by the Australian Parliament, aims to protect human health and the environment by regulating gene technology, including genetically modified organisms. The Act established a comprehensive framework to identify and manage potential risks associated with the release of genetically modified organisms, ensuring a balance between innovation and safety. In 2016, the Office of the Gene Technology Regulator issued an invitation for public comment on the commercial release of genetically modified cotton by Bayer CropScience Pty Ltd. The proposed release involved GlyTol® and GlyTol TwinLink Plus® cotton, genetically modified for herbicide tolerance and insect resistance, respectively. The Regulator sought submissions to finalise the Risk Assessment and Risk Management Plan (RARMP), which concluded that the release posed negligible risk to human health and the environment. The public consultation aimed to inform the decision on whether to issue a licence for the commercial release, aligning with the Act's policy objective of safeguarding public and environmental health while fostering responsible innovation in gene technology.

Scope and Application

The legislation in question concerns the commercial release of genetically modified (GM) cotton in Australia, specifically focusing on the assessment and approval process under the Gene Technology Act 2000. The Act applies to entities such as Bayer CropScience Pty Ltd, which have submitted a licence application for the release of GM cotton varieties. The geographic reach of this application is Australia-wide, subject to any state government restrictions, meaning that if approved, the GM cottons can be commercially released throughout the country. The Act is administered by the Gene Technology Regulator, who is responsible for assessing the potential risks to human health and the environment posed by the proposed GM cotton varieties and determining whether the application should be approved. The Regulator is seeking public submissions to inform the finalisation of the Risk Assessment and Risk Management Plan (RARMP) for this application, which is currently under review. The Act does not specify any particular exclusions, but the process does involve rigorous assessment and risk management to ensure the protection of health and the environment. The application of the Act may be extended or restricted through subordinate instruments that establish specific conditions or guidelines for the assessment and release of GM organisms.

Key Provisions

The main operative sections of the legislation, as outlined in the Gazette, pertain to the assessment and potential commercial release of genetically modified (GM) cotton in Australia. Specifically, section 59 of the Gene Technology Act 2000 mandates that the Gene Technology Regulator review the licence application (DIR 143) submitted by Bayer CropScience Pty Ltd for the commercial release of two types of GM cotton: GlyTol® cotton and GlyTol TwinLink Plus® cotton. Section 60A requires the Regulator to prepare a Risk Assessment and Risk Management Plan (RARMP) which evaluates the risks to human health and the environment associated with the proposed GM cotton release. Section 61 specifies the criteria that the Regulator must consider when determining whether to issue a licence for the commercial release. The Act imposes obligations on Bayer CropScience Pty Ltd to provide comprehensive data and information regarding the GM cotton's genetic modifications, its potential environmental impact, and its safety for human health. The Regulator, under sections 60 and 61, must conduct a thorough assessment of this information, prepare a RARMP, and consult with relevant stakeholders, including the public, to ensure a robust evaluation of the risks. Additionally, the Regulator must propose draft licence conditions that ensure ongoing oversight of the GM cotton release, as outlined in section 62. Breaches of the obligations and requirements set out in the Gene Technology Act 2000 may result in both civil and criminal consequences. Under section 76, any person who contravenes a licence condition may be liable for penalties, including fines up to $1.1 million for individuals and $5.5 million for bodies corporate, as stipulated in section 77. Furthermore, under section 78, any person who causes or permits a prohibited action may face criminal charges and fines of up to $66,000 for individuals and $330,000 for bodies corporate. These provisions are designed to ensure compliance with the regulatory framework and to protect public health and the environment.